An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

ClinicalTrials.gov ID: NCT01136967

Public ClinicalTrials.gov record NCT01136967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.

Study identification

NCT ID: NCT01136967
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eisai Inc.; Industry
Enrollment: 182 participants

Conditions and interventions

Conditions

Interventions

Lenvatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2010
Primary completion: Mar 31, 2013
Completion: Oct 31, 2014
Last update posted: Nov 12, 2019

2010 – 2014

United States locations

U.S. sites: 79
U.S. states: 23
U.S. cities: 79

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Tucson	Arizona	—	—
Not listed	Los Angeles	California	—	—
Not listed	San Francisco	California	—	—
Not listed	Aurora	Colorado	—	—
Not listed	Boulder	Colorado	—	—
Not listed	Colorado Springs	Colorado	—	—
Not listed	Denver	Colorado	—	—
Not listed	Lakewood	Colorado	—	—
Not listed	Littleton	Colorado	—	—
Not listed	Lone Tree	Colorado	—	—
Not listed	Longmont	Colorado	—	—
Not listed	Parker	Colorado	—	—
Not listed	Thornton	Colorado	—	—
Not listed	Bonita Springs	Florida	—	—
Not listed	Bradenton	Florida	—	—
Not listed	Cape Coral	Florida	—	—
Not listed	Clearwater	Florida	—	—
Not listed	Englewood	Florida	—	—
Not listed	Fort Myers	Florida	—	—
Not listed	Gainesville	Florida	—	—
Not listed	Naples	Florida	—	—
Not listed	North Port	Florida	—	—
Not listed	Orlando	Florida	—	—
Not listed	Palm Harbor	Florida	—	—
Not listed	Port Charlotte	Florida	—	—
Not listed	Sarasota	Florida	—	—
Not listed	Sebring	Florida	—	—
Not listed	Tampa	Florida	—	—
Not listed	Venice	Florida	—	—
Not listed	Louisville	Kentucky	—	—
Not listed	Boston	Massachusetts	—	—
Not listed	Detroit	Michigan	—	—
Not listed	Burnsville	Minnesota	—	—
Not listed	Coon Rapids	Minnesota	—	—
Not listed	Edina	Minnesota	—	—
Not listed	Fridley	Minnesota	—	—
Not listed	Maplewood	Minnesota	—	—
Not listed	Minneapolis	Minnesota	—	—
Not listed	Saint Paul	Minnesota	—	—
Not listed	Woodbury	Minnesota	—	—
Not listed	Southaven	Mississippi	—	—
Not listed	St Louis	Missouri	—	—
Not listed	Henderson	Nevada	—	—
Not listed	Las Vegas	Nevada	—	—
Not listed	Lebanon	New Hampshire	—	—
Not listed	Morristown	New Jersey	—	—
Not listed	New York	New York	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Cleveland	Ohio	—	—
Not listed	Columbus	Ohio	—	—
Not listed	Eugene	Oregon	—	—
Not listed	Portland	Oregon	—	—
Not listed	Springfield	Oregon	—	—
Not listed	Tualatin	Oregon	—	—
Not listed	Bethlehem	Pennsylvania	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Bartlett	Tennessee	—	—
Not listed	Franklin	Tennessee	—	—
Not listed	Gallatin	Tennessee	—	—
Not listed	Germantown	Tennessee	—	—
Not listed	Hermitage	Tennessee	—	—
Not listed	Lebanon	Tennessee	—	—
Not listed	Memphis	Tennessee	—	—
Not listed	Murfreesboro	Tennessee	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Smyrna	Tennessee	—	—
Not listed	Bedford	Texas	—	—
Not listed	Dallas	Texas	—	—
Not listed	Grapevine	Texas	—	—
Not listed	Houston	Texas	—	—
Not listed	Arlington	Virginia	—	—
Not listed	Fairfax	Virginia	—	—
Not listed	Gainesville	Virginia	—	—
Not listed	Leesburg	Virginia	—	—
Not listed	Winchester	Virginia	—	—
Not listed	Woodbridge	Virginia	—	—
Not listed	Vancouver	Washington	—	—
Not listed	Madison	Wisconsin	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01136967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2019 · Synced Sep 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01136967 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →